Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10356
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHerbertson, R Aen
dc.contributor.authorLee, S Ten
dc.contributor.authorTebbutt, Niall Cen
dc.contributor.authorScott, Andrew Men
dc.date.accessioned2015-05-15T23:47:00Z
dc.date.available2015-05-15T23:47:00Z
dc.date.issued2007-04-13en
dc.identifier.citationAnnals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo 2007; 18(11): 1774-81en
dc.identifier.govdoc17434894en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/10356en
dc.description.abstractThe therapeutic options and subsequent survival of colorectal cancer (CRC) patients has increased substantially over recent years. While surgical excision of the primary cancer results in cure of approximately 50% of patients, recurrence and metastatic disease still remains a significant cause of death. Although resection of liver or lung metastases can result in cure, relapse rates remain high, indicating that patient selection needs improvement. Positron emission tomography (PET) technology has a great deal to offer with respect to CRC management, particularly in the setting of patient selection for metastasectomy and in the evaluation of possible recurrent disease, however it has not yet become a routine part of the management of all CRC patients. This review article aims to discuss the current and future implications of PET technology in the optimal management of CRC patients throughout their care pathway.en
dc.language.isoenen
dc.subject.otherColorectal Neoplasms.mortality.pathology.radionuclide imaging.surgeryen
dc.subject.otherFemaleen
dc.subject.otherFluorodeoxyglucose F18.diagnostic useen
dc.subject.otherForecastingen
dc.subject.otherHumansen
dc.subject.otherImmunohistochemistryen
dc.subject.otherMaleen
dc.subject.otherNeoplasm Recurrence, Local.pathology.radionuclide imaging.therapyen
dc.subject.otherNeoplasm Stagingen
dc.subject.otherPositron-Emission Tomography.standards.trendsen
dc.subject.otherPrognosisen
dc.subject.otherRisk Factorsen
dc.subject.otherRoleen
dc.subject.otherSensitivity and Specificityen
dc.subject.otherSurvival Analysisen
dc.titleThe expanding role of PET technology in the management of patients with colorectal cancer.en
dc.typeJournal Articleen
dc.identifier.journaltitleAnnals of oncology : official journal of the European Society for Medical Oncology / ESMOen
dc.identifier.affiliationrebecca.herbertson@ludwig.edu.auen
dc.identifier.affiliationLudwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, Harold Stokes Building, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.1093/annonc/mdm108en
dc.description.pages1774-81en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/17434894en
dc.type.austinJournal Articleen
local.name.researcherScott, Andrew M
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

62
checked on Dec 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.